Big Pharma Presence In Gene Therapy Dealmaking Validates Technology
Executive Summary
For several years, smaller biotechs have been advancing gene therapies and delivery technology. Big Pharma companies have increasingly been becoming involved through deal-making, and are ready to take gene therapy to the next level.
You may also be interested in...
Partnering In Cell And Gene Therapy Is A Unique Endeavor
Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.
Cellectis Moves First Off-The-Shelf CAR-T Into US Clinical Trials
UCART123 is behind the initial wave of CAR-T drugs for cancer but could have a big advantage as an allogeneic, or off-the-shelf, option. A Phase I trial is now under way in patients with acute myeloid leukemia.
Deals In Depth: February 2020
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
Need a specific report? 1000+ reports available
Buy Reports